DUBLIN--(BUSINESS WIRE)--The "Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
Global Overactive Bladder Treatment Market was valued at USD 4978.09 Million in the year 2018. New emerging technologies and drug development with expanding health expenditure and infrastructure, rising number of elderly people etc. is driving the Overactive Bladder Treatment market. Further, advent of combination therapy, rising drug approval will bolster the overactive bladder treatment market. In addition, the ongoing developments and advancements of treatments in pharmaceutical industry will create the demand for high-efficient Overactive Bladder Treatment that are likely to boost the growth of Overactive Bladder Treatment market across all over the globe.
By Medication, Oxybutynin has been estimated to propel the market growth globally mainly owing to its cost effectiveness, good efficiency and lower rate of adherence in OAB treatment. By Therapy, BOTOX Treatment will have high growth rate, due to the fact that BOTOX is more cost-effective, even when performed in the hospital under general anesthesia. However, it can also be performed under local anesthesia. Furthermore, Botox is one-step procedure and does not require the implantation of a foreign body. BOTOX Therapy is an acceptable treatment for physicians as well and requires fewer extra skills beyond those necessary for a cystoscopic. Botox is safe, with the only side effect being the temporary need to catheterize in 6% of cases and UTI in 18% of cases.
Based on Therapy, SNM Therapy is expected to propel and have higher growth rate owing to its significantly higher completely dry rates and higher zero pad usage, improvement in frequency/urgency, and causes no change in voiding efficiency. Further, SNM therapy is more holistic than BOTOX Therapy and is a restorative therapy and returns function back to the patient. SNM does carry more complications (about 20%), mostly comprising undesirable stimulation and pain at the implant site.
Key Topics Covered:
1. Report scope & Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
2.1 Asia Pacific region to witness augmented growth in the forecast period.
2.2 Contribution in Research and Development activities to expand the overactive bladder treatment products.
3. Global Overactive Bladder Product Outlook
4. Global Overactive Bladder Treatment Market: An Analysis
4.1 Market Size, By Value, Year 2014-2024
5. Global Overactive Bladder Treatment Segmentation By Medication(By Value)
5.1 Competitive Scenario of Global Overactive Bladder Treatment Market - By Medication
5.2 Oxybutynin - Market Size and Forecast (2014-2024)
5.3 Tolterodine - Market Size and Forecast (2014-2024)
5.4 Tropism - Market Size and Forecast (2014-2024)
5.5 Solifenacin - Market Size and Forecast (2014-2024)
5.6 Mirabegron - Market Size and Forecast (2014-2024)
5.7 Others - Market Size and Forecast (2014-2024)
6. Global Overactive Bladder Treatment Market Segmentation By Therapy(By Value)
6.1 Competitive Scenario of Global Overactive bladder treatment: By Therapy
6.2 BOTOX- Market Size and Forecast (2014-2024)
6.3 SNM Therapy- Market Size and Forecast (2014-2024)
6.4 PTNS Therapy-Market Size and Forecast (2014-2024)
7. Global Overactive Bladder Treatment Market: Regional Analysis
7.1 Competitive Scenario of Global Overactive Bladder Treatment: By Region
8. North America Overactive Bladder Treatment Market: By Analysis
8.1 North America Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.2 Market Segmentation By Medication
8.3 Market Segmentation By Therapy
8.4 North America Global Overactive Bladder Treatment Market: Country Analysis
8.5 Market Opportunity Chart of North America Overactive Bladder treatment Market - By Country, By Value (Year-2024)
8.6 Competitive Scenario of North America Overactive Bladder treatment : By Country
8.7 United States Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.8 United States Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.9 Canada Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.10 Canada Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
8.11 Mexico Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
8.12 Mexico Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
9. Europe Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2014-2024)
10. APAC Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2014-2024)
11. ROW Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2014-2024)
11.1 ROW Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
11.2 Market Segmentation By Medication
11.3 Market Segmentation By Therapy
12. Global Overactive Bladder Treatment Market Dynamics
12.1 Global Overactive Bladder Treatment Market Drivers
12.2 Global Overactive Bladder Treatment Market Restraints
12.3 Global Overactive Bladder Treatment Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.2 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Medication (Year 2024)
13.3 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Therapy (Year-2024)
13.4 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)
14. Pipeline Product Analysis
14.1 New Technologies in Overactive Bladder Treatments
14.2 Key Pipeline Drugs in Overactive Bladder Treatment Market
14.3 Key new operative therapies in Overactive Bladder Treatment Market
15. Competitive Landscape
15.1 Market Share Analysis
15.2 SWOT Analysis
15.3 Porter's Five Force Analysis
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Astellas Pharma Inc.
16.2 Allergan
16.3 Pfizer Inc.
16.4 Laborie
16.5 Teva Pharmaceutical
16.6 Intas Pharmaceutical Ltd.
16.7 Axonics Modulation Technologies, Inc.
16.8 Apotex
16.9 Macleods Pharmaceuticals Ltd.
16.10 Sanofi S.A.
For more information about this report visit https://www.researchandmarkets.com/r/cv9d93
